Kuros reports 163% growth in direct MagnetOs sales and 153% increase in total medical device sales for the full year 2023
Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million…
Financial highlights Direct MagnetOs sales grew by 163% to CHF 31.7 million in 2023, climbing from CHF 12.1 million…
Kuros Biosciences (“Kuros” or “the Company”), a leader in next generation bone graft technologies, today announced it wi…
MagnetOs™ Granules becomes the third product in the MagnetOs portfolio to receive FDA clearance to market for inter…
. New level 1 data from the MAXA Clinical Trial comparing standalone MagnetOs to the gold standard autograft in the ch…
In the MAXA trial, standalone MagnetOs outperformed the gold standard autograft by 73% in posterior spinal fusion in…
The US solar company iSun, Inc. (NASDAQ: ISUN) (“iSun”) and the German agrivoltaics pioneer Next2Sun Mounting Systems G…
BOS Balance of Storage Systems AG, a pioneering German energy tech company, has successfully deployed a solar island sys…
BOS Balance of Storage Systems AG, a developer of battery and energy storage solutions, announces its ongoing initiative…
MagnetOs is the first open fibrillar collagen matrix bone graft substitute to receive clearance to market for interb…
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels in th…